A new report from the linkurl:American Medical Student Association;http://www.amsa.org/ (AMSA) paints a gloomy picture of how US medical schools are failing to craft policies that keep the pharmaceutical industry at arm's length. The AMSA's linkurl:PharmFree Scorecard 2008,;http://www.amsascorecard.org/ released yesterday (June 3), surveyed 150 medical school's across the country, asking about the institutions' policies to limit linkurl:conflicts of interest;http://www.the-scientist.com/blog/display/54300/ with pharmaceutical companies. According to the scorecard, only seven of the 150 medical schools received As, while some perennial physician training powerhouses - such as Harvard Medical School and New York University School of Medicine - received Fs. But are the nation's medical schools really failing at avoiding conflicts of interest? Perhaps not as badly as the AMSA's scorecard would have you believe. New York University, like 30 percent of the schools surveyed, simply didn't respond to the AMSA's request for policies. Harvard, on the other hand, may have gotten an F...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?